Genprex, Inc. 8-K

What Happened Genprex, Inc. (GNPX) announced on June 10, 2026 that Nasdaq’s Listing Qualifications Staff sent a letter determining the company is not in compliance with Nasdaq Listing Rule 5550(a)(2) because its common stock closed below $1.00 for the prior 30 consecutive business days. Nasdaq determined Genprex is not eligible for the standard 180‑day compliance period because the company effected a reverse stock split on October 21, 2025. Genprex said it will timely request a hearing before a Nasdaq Hearings Panel, which automatically stays any delisting action pending the hearing and any Panel-granted extension.

Key Details

• Nasdaq rule cited: Listing Rule 5550(a)(2) (minimum $1.00 bid price); ineligibility under Rule 5810(c)(3)(A)(iv) due to Oct 21, 2025 reverse split.
• Date of Nasdaq letter: June 10, 2026.
• To regain compliance the closing bid must be ≥ $1.00 for at least 10 consecutive business days (subject to Panel discretion to extend).
• Company will request a hearing and may consider a reverse stock split to meet the bid price; no assurance of Panel relief or successful compliance.

Why It Matters A Nasdaq delisting (or loss of listing) could materially affect Genprex’s stock liquidity, market visibility and ability to raise capital. The company’s immediate path is a request for a Nasdaq hearing and potential corporate actions (including another reverse split) to restore the share price above $1.00. Investors should note the company also filed an update to its risk factors describing these events and the related uncertainties.